Romiplostim
- PDF / 141,369 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 43 Downloads / 142 Views
1
Romiplostim Asthenia, fatigue, bleeding and headache: 2 case reports Two paediatric patients receiving romiplostim developed headache, fatigue and asthenia (patient 1) or mucocutaneous bleeding (patient 2). [Times to reaction onset, treatments and outcomes not stated]. Patient 1 was a 13-year-old boy who was diagnosed with primary immune thrombocytopenia. After a lack of response to conventional treatments, he started receiving SC romiplostim 1 µg/kg/week. The dose was then adjusted according to platelet counts, to a maximum of 2 µg/kg/week. With the onset of treatment he reported asthenia and fatigue during moderate exercise; cardiopulmonary causes were excluded. He also reported occasional headaches after starting the drug. Patient 2, a 4-year-old boy, also had a lack of response to conventional treatments for immune thrombocytopenia. He started receiving SC romiplostim, at an initial dose of 1 µg/kg, followed by weekly doses of up to 6 µg/kg. Romiplostim was suspended for platelet counts > 250 000/µL, and he experienced two episodes of mucocutaneous bleeding. Author comment: "The drug was considered to be safe, as there were only mild adverse reactions." Vilaplana VE, et al. Use of romiplostim for primary immune thrombocytopenia in children. Pediatric Hematology and Oncology 29: 197-205, No. 2, Mar 2012. Available from: URL: http://dx.doi.org/10.3109/08880018.2011.629401 803070688 Spain
0114-9954/10/1402-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 19 May 2012 No. 1402
Data Loading...
